

For personal use only

nanosonics

Infection Prevention. For Life.



Nanosonics Limited
Building A, Level 1, 11 Talavera Road
Macquarie Park
NSW 2113 Australia

Welcome to the 2024
Annual General Meeting
12 November 2024



Steve Sargent
Non-Executive Director
and Chairman



Michael Kavanagh
CEO, President and
Managing Director



Lisa McIntyre
Non-Executive Director



David Fisher
Non-Executive Director



Tracey Batten
Non-Executive Director



Marie McDonald
Non-Executive Director



Geoff Wilson
Non-Executive Director



Larry Marshall
Non-Executive Director

For personal use only


How to ask a Question

- To ask a written question select the Q & A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and press the send button
- To ask a verbal question follow the instructions below the broadcast window.

The screenshot displays the Q & A section of the Nanosonics interface. At the top, there are four navigation icons: Broadcast (monitor), Vote (document), Q & A (speech bubble), and Documents (folder). The Q & A icon is highlighted with a red underline. Below the navigation bar is a large text input area with the placeholder text "Your question(s)". Underneath this area, there is a message: "You may enter a question using the field below." followed by a "Select Topic" dropdown menu. Below the dropdown, a note states "Questions are limited to 2000 characters." At the bottom, there is a smaller text input field with a character count of "0 character(s)" and a "Send" button.

How to Vote

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote “click here to change your vote” at any time until the poll is closed



For personal use only

nanosonics

Infection Prevention. **For Life.**



2024 Annual General Meeting

Chairman's Address
Steven Sargent
Non-executive Director and Chairman



GROWTH IN ULTRASOUND & ENDOSCOPY GENERALLY

Both ultrasound and endoscope modalities remain as relevant as ever. Each continues to be a mainstay of healthcare delivery globally.



HEALTHCARE ACQUIRED INFECTIONS

The negative impacts on patients and healthcare systems caused by healthcare acquired infections remains significant.



DIGITISATION & AUTOMATION

The digital world is permeating all aspects of healthcare; replacing arcane documentation and records. Automation, data and traceability are becoming a cornerstone of infection prevention.

Executing on the opportunity

We continue to **lead** the **Ultrasound Reprocessing** market through our trophon2 technology



We anticipate that CORIS will **transform** the **Endoscope Reprocessing** market



For personal use only

Key FY25 Targets

Caring for our Planet



- 100% renewable electricity for Australian and United States (circa 100% of scope 1&2).
- Work with transport providers on reducing scope 3 emissions

Caring for our Partners



- Conduct onsite modern slavery audits in conjunction with quality audits with tier one suppliers
- Continue growth in the number of patients protected from cross contamination from ultrasound probes

Caring for our Customers & their Patients



- Gender diversity progress towards 40:40:20 at Board, Executive & Senior Leader level
- Continue growth in water savings
- Zero Product recalls and regulatory complaints

Caring for our People



- Employee Engagement 74%
- WGEA - to maintain or increase the level of women in our total global workforce (44% in 2024) and represented in the global senior leader level at 44%





Steve Sargent
Non-Executive Director
and Chairman



Michael Kavanagh
CEO, President and
Managing Director



Lisa McIntyre
Non-Executive Director



David Fisher
Non-Executive Director



Tracey Batten
Non-Executive Director



Marie McDonald
Non-Executive Director



Geoff Wilson
Non-Executive Director



Larry Marshall
Non-Executive Director

For personal use only

For personal use only

nanosonics

**Infection
Prevention.
For Life.**



2024 Annual General Meeting

CEO Address
Michael Kavanagh
CEO and President

FY24 Key highlights

For personal use only



Revenue

- Total revenue: \$170.0 million, up 2% on prior period (0% in constant currency¹)
- H2 revenue: \$90.4 million, up 14% on FY24 H1

Global installed base

- Up 2,340 units to 34,790 units globally, a 7% increase in the last 12 months

trophon[®]2 upgrades

- 1,510 units, down 17% compared to prior period
- H2 upgrades: 890 units, up 44% on FY24 H1

Gross profit margin

- For the year: 77.9%
- H2: 76.3% down 3.4 pts on the 79.7% in FY24 H1 due to the one-off production reduction

Operating expenses

- \$125.6 million, up 10% on prior period
- Includes investments in product expansion (CORIS), geographical expansion, and over \$1 million for new ERP system

Operating profit before tax

- \$13.0 million including ongoing investments in growth strategy. Trophon only PBT of \$40.4 million

Free cash flow and cash

- Free cash flow of \$20.4 million, with cash and cash equivalents of \$129.6 million at 30 June with no debt

CORIS[®] progress

- FDA de novo regulatory application submitted and currently under review.

1. Constant currency removes the impact of foreign exchange rate movements to facilitate comparability of operational performance. This is done by converting the current year sales of entities that use currencies other than Australian dollars at the average rates that were applicable in the prior year. The average exchange rate used for the Company's major foreign currency (USD) for the half year was 0.66 (2023:0.67).

Business outlook for FY25

The Company is optimistic about the potential for growth in the trophon ultrasound reprocessing sector and its wider strategic objectives for expansion, particularly regarding the prospects with CORIS following regulatory approval.

8% - 12%¹ revenue growth

- Growing capital revenue with increased unit volumes over FY24.
- Increasing consumables and service revenue aligned with growth in installed base and service contract coverage.

77% - 79%¹ gross margin

- With a planned return to higher production volumes in FY25 and with anticipated increase in unit volume sales, gross margin is expected to return to 77-79%.

6% - 10%¹ operating expenses growth

- Includes ongoing investment in CORIS commercialisation readiness, R&D and geographical expansion.
- One-off expenses associated with the introduction of a new ERP.
- Expecting positive operating leverage in trophon only business.

All guidance is subject to uncertainty in relation to the impact of inflation on hospital budgetary pressures and healthcare costs in general.

1. The FY25 outlook assumes a USD/AUD rate of 0.67.

For personal use only

Our Mission

We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted and introducing innovative technologies that deliver improved standards of care.

Our Aspiration

Transform medical device reprocessing for improved patient safety and better health outcomes.



Our aspiration and strategy

Transform medical device reprocessing for improved patient safety and better health outcomes

For personal use only

VALUE CREATION



By establishing new standards of care and category leadership

Leading ultrasound reprocessing

Transforming endoscope reprocessing

R&D, strategic partnerships and M&A



Growing, expanding value for and protecting our customer base

International expansion

Customer value expansion

Excellence in customer experience



Operational excellence will deliver value for all stakeholders

R&D and bioscience innovation

Medical and clinical affairs impact

Asset allocation and operational efficiencies

Manufacturing and supply chain scalability and continuity

ORGANISATIONAL FOUNDATIONS



Strong organisational foundations will underpin our achievements

Excellent talent

Digital and data transformation


Quality

Sustainability

Significant global opportunity



A GLOBAL INSTALLED
BASE OPPORTUNITY OF
140,000¹ UNITS



25% market
penetration




NORTH AMERICA

Installed Base Opportunity

60,000¹
UNITS

Market Penetration



Strong Fundamentals

- Direct infrastructure in place to access Hospital opportunity
- Channel partners in place to capture Private market opportunity
- Significant installed base for annuity revenue optimization through value adding eco system




EUROPE AND MIDDLE EAST

Installed Base Opportunity

40,000²
UNITS

Market Penetration



Strengthening Fundamentals

- Direct in markets with strongest fundamentals
- Strategic partnership with Eco Lab in France and ME
- Expanded offerings to leverage current investments in UK and Ireland




ASIA PACIFIC

Installed Base Opportunity

40,000²
UNITS

Market Penetration



Strengthening Fundamentals and Expanding Markets

- Ongoing growth and leadership in ANZ
- Focus on Japan with awareness increasing and fundamentals improving

1. Nanosonics analysis last updated in 2021 based on updated ultrasound information commissioned by Nanosonics and an estimated trophon to ultrasound attachment rate.
2. Based on Nanosonics' estimate from around 2011. While current data is not readily available for the Asia Pacific and Europe and Middle East regions, the Company considers that the ultrasound market has grown in these regions since the initial estimate of the Installed Base Opportunity was made.

For personal use only

Ongoing NA market opportunity

Approximately 270,000 ultrasound devices in use in North America across....

5,700 relevant hospitals with departments using ultrasound¹



Large (~250)
(>501 beds)



Medium (~750)
(251-500 beds)



Small (4,700)
(<250 beds)

Together with approximately 12,000 relevant private physician centres¹



trophon TAM
NORTH AMERICA²
60,000 units

trophon devices established as standard of care with **50% market penetration**

Remaining 30,000 TAM

Hospital market ~ 20,000
Private physician market ~ 10,000


1. Nanosonics analyses of North America hospitals and procedures data conducted in 2024
2. Nanosonics analysis last updated in 2021 based on ultrasound information commissioned by Nanosonics.

For personal use only

trophon growth and value opportunity

We strive to deliver continuous value over the lifetime of trophon devices by driving improved compliance with HLD standards and owning the ultrasound reprocessing value chain through eco-system & digital offerings.

For personal use only



- GROWTH DRIVERS**
- Installed base growth
 - Capital Upgrade growth
 - Usage growth
 - Eco System growth
 - Service growth
 - Digital Solution growth


Europe fundamentals improving



Strengthening Fundamentals

- Direct in markets with strongest fundamentals
- Strategic partnership with Eco Lab in France and ME
- Expanded offerings to leverage current investments in UK and Ireland

FY24 Total revenue \$10.1m



1. Based on Nanosonics' estimate from around 2011. While current data is not readily available for the Asia Pacific and Europe and Middle East regions, the Company considers that the ultrasound market has grown in these regions since the initial estimate of the Installed Base Opportunity was made.

For personal use only



Japan fundamentals improving

For personal use only



Japan Market Development Progressing

- Japanese Society of Sonographer (JSS) has **published a new guideline** recommending Spaulding classification based HLD practice for ultrasound transducers
- Survey in recent symposium at Japanese Society of Infection Prevention & Control (JSIPC) demonstrated awareness of risk increasing.



1. Based on Nanosonics' estimate from around 2011. While current data is not readily available for the Asia Pacific and Europe and Middle East regions, the Company considers that the ultrasound market has grown in these regions since the initial estimate of the Installed Base Opportunity was made.

For personal use only

Leading Ultrasound Reprocessing

Significant ongoing
growth opportunity



nanosonics
Infection Prevention. For Life.




Transforming endoscope reprocessing

For personal use only

Adverse event reports for endoscopes continue to grow

Adverse events continue to grow and reprocessing failures and infections have been reported across all major endoscope types¹

Numerous outbreaks caused by multi-drug resistant organisms continue to occur, with significant impact to healthcare facilities and patients



- Excess of 34,000 endoscope-related adverse events in past 12 months
- Gastrosopes and colonoscopes most commonly involved

- 5 multidrug-resistant organisms (MDRO) outbreaks with 1,527 patients exposed have been reported in the peer-reviewed literature YTD in 2024 in the USA.²⁻⁶
- Some patients became carriers and did not show active signs of infection for up to 320 days after the endoscopic procedure.²
- Authors noted published outbreaks greatly underestimate the true rate of exposure and infection²⁻⁴ and biofilm was implicated in several outbreaks.³⁻⁵
- One outbreak investigation alone in the US involved 77 healthcare professionals to manage.⁷

References: 1. Analysis of FDA MAUDE database by Ofstead and Associates <https://www.linkedin.com/posts/ofstead-%26-associates-2>. Suleyman, G. et al. Infect Control Hosp Epidemiol. (2024) doi:10.1017/ice.2024.36. 3. Cimen, C. et al. Antimicrob. Resist. Infect. Control 13, 31 (2024). 4. van der Ploeg, K. et al. J. Hosp. Infect. 147, 56–62 (2024). 5. Yang A. et al. Infect Control Hosp Epidemiol. Apr 2:1-6. (2024) 6. Codman et al. Am J Infect Control.2024;52 7. Gubler et al. Am J Infect Control. 2024:52.

For personal use only

CORIS

CORIS aims to deliver safer endoscopes to patients through superior cleaning

Designed to deliver better cleaning outcomes

Combining a unique mode of action with the CORIS QUANTUM cleaning agent that can remove even the toughest biofilm from all channels, even the smallest ones that cannot be brushed.

Automating the cleaning process

Removing the risk of human error in the cleaning process to provide reliable cleaning outcomes every time.

Improving the safety of reprocessing staff

Removing the manual actions that cause fatigue and injury via its Smart Drain technology, reducing the risk of splashes and aerosolisation of contaminants.

Increasing the efficiency of the facility

Automating traceability tasks and releasing staff from hands-on reprocessing activities to perform other duties.



Evidence of biofilm formation in endoscope channels




Published data:

Biofilm found in clinical lumens¹

Study withdrew clinically used gastroscopes, replaced lumens, then returned the scopes to clinical use.

At 30- and 60-day timepoints the lumens were recovered and sent for analysis

Despite reprocessing, biofilm or probable biofilm was found in all locations sampled





Preliminary data:

Biofilm presence in clinical lumens²

Study underway to assess lumens of clinically used endoscopes for the presence of biofilm at the time of servicing.

- Staining and SEM images undertaken for small and large channels
- Preliminary data show biofilm or probable biofilm in multiple samples despite reprocessing.



CORIS delivers cleaning results far exceeding manual cleaning

Key findings

- CORIS significantly outperformed manual cleaning in all channels across all markers including protein, total organic carbon and viable bacteria.
- 1.4-mm and 3.7-mm channels were tested, representing air/water/auxiliary and suction/biopsy channels respectively.
- Manual cleaning failed to remove biofilm from the air/water and auxiliary channels.

Journal of Hospital Infection 130 (2024) 71–72
Available online at www.sciencedirect.com
Journal of Hospital Infection
Journal homepage: www.elsevier.com/locate/jhin

Comparison of two endoscope channel cleaning approaches to remove cyclic build-up biofilm

L. Moshkanbaryans^{a,*}, V. Shah^{b,†}, L.Y. Tan^c, M.P. Jones^d, K. Vickery^e, M. Alfa^f, J. Burdach^{a,*}

^a Medical Affairs, Nanosonics Ltd, Sydney, Australia
^b Bioscience, Nanosonics Ltd, Sydney, Australia
^c Clinical Affairs, Nanosonics Ltd, Sydney, Australia
^d School of Psychological Sciences, Faculty of Medicine, Health & Human Sciences, Macquarie University, Sydney, Australia
^e Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
^f Alfamed Consulting, Winnipeg, Manitoba, Canada




ARTICLE INFO
Article history:
Received 25 February 2024
Accepted 25 May 2024
Available online 1 June 2024

SUMMARY
Introduction: Biofilm contributes significantly to bacterial persistence in endoscope channels. Enhanced cleaning methods capable of removing biofilm from all endoscope channels are required to decrease infection risk to patients. This head-to-head study compared cyclic build-up biofilm removal of an automated endoscope channel cleaner (AECC) with standard manual cleaning according to instructions for use (IFU) in polytetrafluorethylene channels.
Methods: Cyclic build-up biofilm was grown in 1.4-mm (representing air/water and auxiliary channels) and 3.7-mm (representing suction/ biopsy channels) inner diameter polytetrafluorethylene channels. All channels were tested for residual total organic carbon, protein, and viable bacteria. Internationally recognized ISO 15883-5:2021 alert levels were used as cleaning benchmarks for protein (3 µg/cm²) and total organic carbon (6 µg/cm²).
Results: The automated cleaner significantly outperformed manual cleaning for all markers assessed (protein, total organic carbon, viable bacteria) in 1.4-mm and 3.7-mm channels representing air/water/auxiliary and suction/biopsy channels, respectively. Manual cleaning failed to remove biofilm from the air/water and auxiliary channels. According to the IFU, these channels are not brushed, suggesting a potential root cause for a portion of the numerous endoscopy-associated infections reported in the literature.
Conclusion: AECC shows potential to deliver enhanced cleaning over current practice to all endoscope channels and may thereby address infection risk.
© 2024 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Keywords: Biofilm, Endoscope, Manual cleaning, Outbreak, Infection, Contamination

* Corresponding author. Address: Medical Affairs, Building A, Level 1, 11 Talavera Rd, Macquarie Park, Sydney, NSW 2113, Australia.
E-mail address: j.burdach@nanosonics.com (J. Burdach).
† These authors contributed equally to this work.

<https://doi.org/10.1016/j.jhin.2024.05.014>
0195-0701/© 2024 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).



Published in the Journal of Hospital Infection


For personal use only

Large global opportunity for CORIS




More than 60 million flexible procedures annually across major markets

Endoscopy, 60 million annual procedures¹



Manual cleaning costs²

EXAMPLE: Total cost to manually clean a single GI endoscope²



- Projected procedure growth rate of 6% p.a.¹
- The USA is the largest contributor to procedure volume.
- 75% of the total are upper and lower gastro-intestinal (GI) procedures.
- Colonoscopes and gastroscopes are most-commonly used.

Current cost of manual cleaning of endoscopes is estimated to be between USD \$11-\$37.

References: 1 Frost & Sullivan, Endoscope Reprocessing Systems and Software Solutions Market Assessment (US, W. Europe, Australia), 2018. 2. Ofstead, C.L., Quick, M.R., Eiland, J.E. and Adams, S.J., 2017. A glimpse at the true cost of reprocessing endoscopes. International Association of Healthcare Central Service Material Management.

For personal use only

CORIS - the pathway to market¹



United States
Food and
Drug
Administration
(FDA)

De Novo Regulatory Pathway

As CORIS is a completely novel technology platform, Nanosonics is pursuing the FDA's De Novo regulatory pathway in the United States. Approval via this pathway would establish CORIS as a completely new category for endoscope cleaning technology.

CORIS currently under FDA review

- CORIS was submitted for De Novo approval at the end of April 2024 and is now proceeding through the FDA's De Novo review process.
- Upon approval, 510K submissions planned to cover all flexible endoscopes.

1. All research and new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines.

For personal use only

nanosonics

**Infection
Prevention.
For Life.**



2024 Annual General Meeting

Resolutions

Re-election of a Director Ms Marie McDonald

For personal use only



To consider and, if thought fit, to pass the following ordinary Resolution:

That Ms Marie McDonald, who retires as a Director pursuant to the Company's Constitution and, being eligible, offers herself for re-election, be re-elected a Director.

Proxy votes received		Number	%
For	:	196,046,026	98.90
Against	:	1,966,997	0.99
Discretion	:	219,019	0.11
Abstained/Excluded	:	124,831	-

Remuneration Report

To consider and, if thought fit, to pass the following ordinary Resolution:

That the Remuneration Report for the financial year ended 30 June 2024 be adopted.

Proxy votes received		Number	%
For	:	196,343,254	99.38
Against	:	1,006,254	0.51
Discretion	:	224,559	0.11
Abstained/Excluded	:	109,446	-

For personal use only

Resolution 3

Issue of 21,914 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh's 2024 Short Term Incentive grant (2024 STI) under the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following ordinary Resolution:

That approval be given under and for the purpose of ASX Listing Rule 10.14 and for all other purposes for the issue of 21,914 Service Rights to Nanosonics' Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh's 2024 STI, on the terms and conditions set out in the Explanatory Notes accompanying this Notice of Meeting and the Nanosonics Equity Plan Rules (as amended from time-to-time).

Proxy votes received		Number	%
For	:	196,847,682	99.62
Against	:	562,342	0.28
Discretion	:	209,293	0.10
Abstained/Excluded	:	737,556	-

For personal use only

Issue of 470,877 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2024 Long-Term Incentive grant (2024 LTI) under the Nanosonics Equity Plan

To consider and, if thought fit, to pass the following ordinary Resolution:

That approval be given under and for the purpose of ASX Listing Rule 10.14 and for all other purposes for the issue of 470,877 Performance Rights to Nanosonics’ Chief Executive Officer and President, Mr Michael Kavanagh, under the Nanosonics Equity Plan in respect of Mr Kavanagh’s 2024 LTI, on the terms and conditions set out in the Explanatory Notes accompanying this Notice of Meeting and the Nanosonics Equity Plan Rules (as amended from time-to-time).

Proxy votes received		Number	%
For	:	196,219,704	99.30
Against	:	1,169,067	0.59
Discretion	:	218,384	0.11
Abstained/Excluded	:	749,718	-

For personal use only

Resolution 5

Re-insertion of Proportional Takeover Provisions in Constitution

To consider and, if thought fit, to pass the following special Resolution:

That the proportional takeover provisions in clause 14 of the Company's Constitution be renewed for a period of three years commencing on the day this special Resolution is passed.

Proxy votes received		Number	%
For	:	197,795,082	99.83
Against	:	111,760	0.06
Discretion	:	223,654	0.11
Abstained/Excluded	:	226,377	-


For personal use only

How to ask a Question

- To ask a written question select the Q & A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and press the send button
- To ask a verbal question follow the instructions below the broadcast window.

The screenshot displays the Q & A section of the Nanosonics interface. At the top, there are four navigation icons: Broadcast (monitor), Vote (document), Q & A (speech bubble, highlighted with a red underline), and Documents (folder). Below the navigation bar is a large text input area with the placeholder text "Your question(s)". Underneath this area, a message states "You may enter a question using the field below." followed by a "Select Topic" dropdown menu. A note below the dropdown reads "Questions are limited to 2000 characters." At the bottom, there is a smaller text input field with a character count of "0 character(s)" and a "Send" button.

- When the poll is open, select the vote icon at the top of the screen
- To vote, select either For, Against or Abstain
- You will see a vote confirmation
- To change or cancel your vote “click here to change your vote” at any time until the poll is closed



How to ask a Question

- To ask a written question select the Q & A icon
- Select the topic your question relates to from the drop-down list
- Type your question in the text box and press the send button
- To ask a verbal question follow the instructions below the broadcast window.

The screenshot displays the Q & A section of the Nanosonics interface. At the top, there are four navigation icons: Broadcast (monitor), Vote (document), Q & A (speech bubble), and Documents (folder). The Q & A icon is highlighted with a red underline. Below the navigation bar is a large text input area with the placeholder text "Your question(s)". Underneath this area, there is a smaller text box with the instruction "You may enter a question using the field below." and a dropdown menu labeled "Select Topic". Below the dropdown menu, there is a character count "0 character(s)" and a "Send" button. A note above the character count states "Questions are limited to 2000 characters."

- This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.
- Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group).
- While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.
- The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.
- No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based.
- Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials.

nanosonics

Infection Prevention. For Life

Nanosonics Limited
Building A
Level 1
11 Talavera Road
Macquarie Park
NSW 2113 Australia

T +61 2 8063 1600
E info@nanosonics.com.au

www.nanosonics.com.au

ABN 11 095 076 896

